Diquafosol

Diquafosol is a pharmacological agent primarily used in the treatment of dry eye syndrome. It is classified as a P2Y2 receptor agonist, which stimulates the secretion of water and mucin, two essential components of the tear film, from the conjunctival goblet cells and ocular surface epithelium.

Mechanism of Action[edit | edit source]

Diquafosol works by activating the P2Y2 receptors on the ocular surface. This activation stimulates the secretion of water and mucin from the conjunctival goblet cells and ocular surface epithelium. The increased secretion helps to restore the tear film, which is often compromised in patients with dry eye syndrome.

Uses[edit | edit source]

The primary use of Diquafosol is in the treatment of dry eye syndrome. It is particularly effective in patients with aqueous-deficient dry eye, where the tear film is lacking in water. Diquafosol can also be used in the management of Sjögren's syndrome, a systemic autoimmune disease that often presents with dry eye symptoms.

Side Effects[edit | edit source]

Common side effects of Diquafosol include eye irritation, blurred vision, and an unusual taste in the mouth. Less common side effects may include eye pain, redness, or swelling. Patients are advised to seek medical attention if these symptoms persist or worsen.

Contraindications[edit | edit source]

Diquafosol should not be used by patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with severe renal impairment, as the drug is primarily excreted by the kidneys.